Of the Covid windfall, there is almost nothing left in the bag of pharmaceutical laboratories.
Industry giants that had developed treatments for the virus at unprecedented speed during the pandemic saw revenues from those treatments disappear at an equally rapid rate as the virus became endemic and populations grew accustomed to living with it. .
The annual results of major laboratories illustrate this shift.
Forgotten, the billions of euros in profits reaped by Pfizer in 2022. The turnover of the American laboratory fell by 42% in a single year, going from 100 billion dollars to 58.5 billion in a single year.
Demand for its Comirnaty vaccine turned out to be lower than expected, 6 billion euros lower than in 2022. The same was true for its antiviral treatment against Covid, Paxlovid.
Roche also had a difficult landing.
The Swiss laboratory's sales fell by 7% last year...
This article is reserved for subscribers.
You have 84% left to discover.
Flash sale
-70% on digital subscription
I ENJOY IT
Already subscribed?
Log in